Based on these data, we would hypothesize that patients who exhibit PI3K pathway activation, but not oncogene addiction to mutant PIK3CA, will undergo a moderate response to PI3K-mTOR inhibition, which will be sustained over a longer period than patients whose tumours exhibit addiction to mutant PIK3CA. The gene discussed is MTOR; the disease is neoplasm.